Capital Increase / Dilution2026-06-29

Aprogen Biologics Amends CB Issuance Terms

APR

에이프로젠바이오로직스

003060

+0.05

Signal Score

52CNeutral
Score52 / 100

Historical Avg Return (5d)

+0.26%

Data Coverage

100%n=2414

Risk-adjusted indicator based on 2414 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Initial Conversion Price: 2,353 KRW/Share
  • • Minimum Adjustment Price: 1,648 KRW/Share
  • • First Put Option Date: January 1, 2028
  • • First Put Option Rate: 103.0760%

AI Analysis Summary

Aprogen Biologics Inc. has amended its Material Fact Report regarding the issuance of convertible bonds. The initial conversion price is confirmed at 2,353 KRW per share, with a minimum adjustment price of 1,648 KRW. The amendment clarifies the finalization of these prices and details the put option terms for bondholders, with the first exercise date on January 1, 2028, at a rate of 103.0760%. This update provides clarity on the CB terms but does not introduce new financial figures that would significantly alter the initial dilution impact.

Track Korean Market Signals — Free

Sign up free to access live disclosures, AI analysis, and event filters.

Public Beta · No credit card required

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(전환사채권발행결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.